Pet-adapted treatment for newly diagnosed ...
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Pet-adapted treatment for newly diagnosed advanced hodgkin lymphoma (ahl2011): a randomised, multicentre, non-inferiority, phase 3 study
Auteur(s) :
Casasnovas, Rene-Olivier [Auteur]
Bouabdallah, Reda [Auteur]
Brice, Pauline [Auteur]
Lazarovici, Julien [Auteur]
Ghesquieres, Herve [Auteur]
Stamatoullas-Bastard, Aspasia [Auteur]
Dupuis, Jehan [Auteur]
Gac, Anne-Claire [Auteur]
Gastinne, Thomas [Auteur]
Joly, Bertrand [Auteur]
Bouabdallah, Krimo [Auteur]
Nicolas-Virelizier, Emmanuelle [Auteur]
Feugier, Pierre [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Delarue, Richard [Auteur]
Farhat, Hassan [Auteur]
Quittet, Philippe [Auteur]
Berriolo-Riedinger, Alina [Auteur]
Tempescul, Adrian [Auteur]
Edeline, Veronique [Auteur]
Maisonneuve, Herve [Auteur]
Fornecker, Luc-Matthieu [Auteur]
Lamy, Thierry [Auteur]
Delmer, Alain [Auteur]
Dartigues, Peggy [Auteur]
Martin, Laurent [Auteur]
Andre, Marc [Auteur]
Mounier, Nicolas [Auteur]
Traverse-Glehen, Alexandra [Auteur]
Meignan, Michel [Auteur]
Bouabdallah, Reda [Auteur]
Brice, Pauline [Auteur]
Lazarovici, Julien [Auteur]
Ghesquieres, Herve [Auteur]
Stamatoullas-Bastard, Aspasia [Auteur]
Dupuis, Jehan [Auteur]
Gac, Anne-Claire [Auteur]
Gastinne, Thomas [Auteur]
Joly, Bertrand [Auteur]
Bouabdallah, Krimo [Auteur]
Nicolas-Virelizier, Emmanuelle [Auteur]
Feugier, Pierre [Auteur]
Morschhauser, Franck [Auteur]

Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Delarue, Richard [Auteur]
Farhat, Hassan [Auteur]
Quittet, Philippe [Auteur]
Berriolo-Riedinger, Alina [Auteur]
Tempescul, Adrian [Auteur]
Edeline, Veronique [Auteur]
Maisonneuve, Herve [Auteur]
Fornecker, Luc-Matthieu [Auteur]
Lamy, Thierry [Auteur]
Delmer, Alain [Auteur]
Dartigues, Peggy [Auteur]
Martin, Laurent [Auteur]
Andre, Marc [Auteur]
Mounier, Nicolas [Auteur]
Traverse-Glehen, Alexandra [Auteur]
Meignan, Michel [Auteur]
Titre de la revue :
The Lancet. Oncology
Nom court de la revue :
Lancet Oncol.
Date de publication :
2019-01-15
ISSN :
1474-5488
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalatedescalated
METHODS: AHL2011 is a randomised, non-inferiority, phase 3 study done in ...
Lire la suite >BACKGROUND: Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalatedescalated METHODS: AHL2011 is a randomised, non-inferiority, phase 3 study done in 90 centres across Belgium and France. Eligible patients were aged 16-60 years and had newly diagnosed Hodgkin lymphoma, excluding nodular lymphocyte predominant subtype, an Eastern Cooperative Oncology Group performance status score less than 3, a life expectancy of at least 3 months, an Ann Arbor disease stage III, IV, or IIB with mediastinum-to-thorax ratio of 0·33 or greater than or extranodal localisation, and had received no previous treatment for Hodgkin lymphoma. Randomisation was unmasked and done centrally by the permuted block method. Patients were randomly assigned to standard treatment (BEACOPPescalatedescalatedescalatedescalatedescalatedescalated22222222222 RESULTS: From May 19, 2011, to April 29, 2014, 823 patients were enrolled-413 in the standard care group and 410 in the PET-driven group. 346 (84%) of 410 patients in the PET-driven treatment group were assigned to receive ABVD and 51 (12%) to continue receiving BEACOPPescalated CONCLUSIONS: PET after two cycles of induction BEACOPPescalated BACKGROUND: Programme Hospitalier de Recherche Clinique.Lire moins >
Lire la suite >BACKGROUND: Increased-dose bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPescalatedescalated METHODS: AHL2011 is a randomised, non-inferiority, phase 3 study done in 90 centres across Belgium and France. Eligible patients were aged 16-60 years and had newly diagnosed Hodgkin lymphoma, excluding nodular lymphocyte predominant subtype, an Eastern Cooperative Oncology Group performance status score less than 3, a life expectancy of at least 3 months, an Ann Arbor disease stage III, IV, or IIB with mediastinum-to-thorax ratio of 0·33 or greater than or extranodal localisation, and had received no previous treatment for Hodgkin lymphoma. Randomisation was unmasked and done centrally by the permuted block method. Patients were randomly assigned to standard treatment (BEACOPPescalatedescalatedescalatedescalatedescalatedescalated22222222222 RESULTS: From May 19, 2011, to April 29, 2014, 823 patients were enrolled-413 in the standard care group and 410 in the PET-driven group. 346 (84%) of 410 patients in the PET-driven treatment group were assigned to receive ABVD and 51 (12%) to continue receiving BEACOPPescalated CONCLUSIONS: PET after two cycles of induction BEACOPPescalated BACKGROUND: Programme Hospitalier de Recherche Clinique.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
Université de Lille
Université de Lille
Collections :
Équipe(s) de recherche :
Modélisation biopharmaceutique et pharmacocinétique
Date de dépôt :
2019-12-16T14:06:40Z